TW222625B - - Google Patents

Info

Publication number
TW222625B
TW222625B TW081109235A TW81109235A TW222625B TW 222625 B TW222625 B TW 222625B TW 081109235 A TW081109235 A TW 081109235A TW 81109235 A TW81109235 A TW 81109235A TW 222625 B TW222625 B TW 222625B
Authority
TW
Taiwan
Prior art keywords
vasopasms
ischemia
salts
symbols
formula
Prior art date
Application number
TW081109235A
Other languages
English (en)
Chinese (zh)
Inventor
Neidhart Werner
Ramuz Henri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25687870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW222625(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of TW222625B publication Critical patent/TW222625B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Lubricants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Glass Compositions (AREA)
  • Bipolar Transistors (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW081109235A 1991-06-13 1992-11-18 TW222625B (OSRAM)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH176091 1991-06-13
CH151692 1992-05-12

Publications (1)

Publication Number Publication Date
TW222625B true TW222625B (OSRAM) 1994-04-21

Family

ID=25687870

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081109235A TW222625B (OSRAM) 1991-06-13 1992-11-18

Country Status (34)

Country Link
US (1) US5292740A (OSRAM)
EP (1) EP0526708B1 (OSRAM)
JP (1) JPH0730042B2 (OSRAM)
KR (1) KR100235507B1 (OSRAM)
AT (1) ATE197044T1 (OSRAM)
AU (1) AU653604B2 (OSRAM)
BG (1) BG60831B2 (OSRAM)
BR (1) BR9202219A (OSRAM)
CA (1) CA2071193C (OSRAM)
CY (2) CY2306B1 (OSRAM)
CZ (1) CZ281434B6 (OSRAM)
DE (2) DE59209872D1 (OSRAM)
DK (1) DK0526708T3 (OSRAM)
DZ (1) DZ1587A1 (OSRAM)
EE (1) EE03028B1 (OSRAM)
ES (1) ES2152222T4 (OSRAM)
FI (1) FI112216B (OSRAM)
GR (1) GR3035162T3 (OSRAM)
HU (2) HU221203B1 (OSRAM)
IE (1) IE921920A1 (OSRAM)
IL (1) IL102138A (OSRAM)
IS (1) IS2054B (OSRAM)
LU (2) LU90975I2 (OSRAM)
MX (1) MX9202747A (OSRAM)
NL (1) NL300097I1 (OSRAM)
NO (2) NO303826B1 (OSRAM)
NZ (1) NZ243074A (OSRAM)
PT (1) PT526708E (OSRAM)
RO (1) RO111268B (OSRAM)
RU (1) RU2086544C1 (OSRAM)
SG (1) SG54209A1 (OSRAM)
SK (1) SK279006B6 (OSRAM)
TW (1) TW222625B (OSRAM)
ZA (1) ZA924126B (OSRAM)

Families Citing this family (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
WO1991003422A1 (en) * 1989-08-30 1991-03-21 Irwin Fox Disposable oxide carrier for scavenging hydrogen sulfide
US5736509A (en) * 1990-12-14 1998-04-07 Texas Biotechnology Corporation Cyclic peptide surface feature mimics of endothelin
TW224462B (OSRAM) * 1992-02-24 1994-06-01 Squibb & Sons Inc
US5378715A (en) * 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5420123A (en) * 1992-12-21 1995-05-30 Bristol-Myers Squibb Company Dibenzodiazepine endothelin antagonists
US5352800A (en) * 1993-03-11 1994-10-04 Merck & Co., Inc. Process for the production of a novel endothelin antagonist
US5374638A (en) * 1993-03-19 1994-12-20 Merck & Co., Inc. Six membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives used to treat asthma
US5334598A (en) * 1993-03-19 1994-08-02 Merck & Co., Inc. Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives
US5767310A (en) * 1993-03-19 1998-06-16 Merck & Co., Inc. Phenoxyphenylacetic acid derivatives
US5420133A (en) * 1993-03-19 1995-05-30 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
US5401745A (en) * 1993-03-19 1995-03-28 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
CA2121724A1 (en) 1993-04-21 1994-10-22 Toshifumi Watanabe Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6030991A (en) * 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
TW394761B (en) * 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
EP0634175B1 (de) * 1993-07-15 2001-01-10 F. Hoffmann-La Roche Ag Pharmazeutische Kombination, die einen Hemmer des Renin-Angiotensin-Systems und einen Endothelin-Antagonisten enthält
US5686478A (en) * 1993-07-20 1997-11-11 Merck & Co. Inc. Endothelin antagonists
US6140325A (en) * 1993-08-19 2000-10-31 Takeda Chemical Industries, Ltd. Thienopyrimidine derivatives, their production and use
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
JPH09504302A (ja) * 1993-11-01 1997-04-28 日本チバガイギー株式会社 エンドセリン・レセプター・アンタゴニスト
IL111959A (en) * 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) * 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides
US5559135A (en) * 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides
US6268369B1 (en) 1994-11-16 2001-07-31 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
JP3200070B2 (ja) 1994-11-16 2001-08-20 シナプティック・ファーマスーティカル・コーポレーション ジヒドロピリミジン類およびその使用
WO1996016963A1 (de) * 1994-11-25 1996-06-06 F. Hoffmann-La Roche Ag Sulfonamide und deren verwendung als heilmittel
CA2162630C (en) * 1994-11-25 2007-05-01 Volker Breu Sulfonamides
US5837708A (en) * 1994-11-25 1998-11-17 Hoffmann-La Roche Inc. Sulphonamides
CN1064965C (zh) * 1994-11-25 2001-04-25 弗·哈夫曼-拉罗切有限公司 新的磺酰胺类化合物及其作为药物的用途
TW313568B (OSRAM) * 1994-12-20 1997-08-21 Hoffmann La Roche
US5962682A (en) * 1994-12-20 1999-10-05 Hoffmann-La Roche Inc. Aryl- and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists
PL188801B1 (pl) * 1994-12-20 2005-04-29 Fhoffmann La Roche Ag Nowe sulfonamidy i zawierające je preparaty farmaceutyczne
WO1996020177A1 (en) * 1994-12-28 1996-07-04 Kowa Co., Ltd. Pyrimidine derivatives
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5573762A (en) * 1995-04-24 1996-11-12 Genentech, Inc. Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
US5739333A (en) * 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
UA58494C2 (uk) 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9512697D0 (en) * 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
DE19527568A1 (de) 1995-07-28 1997-01-30 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
DE19528418A1 (de) * 1995-08-02 1997-02-06 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
DE19530032A1 (de) * 1995-08-16 1997-02-20 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
HUP9903526A3 (en) * 1995-09-06 2000-07-28 Kowa Co Pyrimidine derivatives and pharmaceutical compositions containing the same
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
CZ260596A3 (en) * 1995-10-12 1997-12-17 Hoffmann La Roche Sulfonamide derivative, process of its preparation and pharmaceutical composition containing thereof
US6228861B1 (en) 1995-11-16 2001-05-08 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6083955A (en) * 1995-12-20 2000-07-04 Yamanouchi Pharmaceutical Co., Ltd. Arylethenesulfonamide derivatives and drug composition containing the same
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
NZ330464A (en) 1996-02-20 2000-04-28 Bristol Myers Squibb Co Methods for the preparation of biphenyl isoxazole sulfonamides
US5958905A (en) * 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US5804585A (en) * 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
US6245773B1 (en) 1996-05-16 2001-06-12 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
WO1998006700A1 (en) * 1996-08-09 1998-02-19 Merck & Co., Inc. Stereoselective deoxygenation reaction
US5985830A (en) * 1996-09-16 1999-11-16 Dalhousie University Use of IGF-I for the treatment of kidney disorders
US5883254A (en) * 1996-11-08 1999-03-16 Hoffmann-La Roche Inc. Process for making pyrimidine derivatives
DE19653024A1 (de) * 1996-12-19 1998-06-25 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
HRP980001A2 (en) * 1997-01-14 1998-10-31 Feng Xu Asymmetric conjugate addition reaction using a chiral additive
US5998625A (en) * 1997-01-14 1999-12-07 Merck & Co., Inc. Asymmetric conjugate addition reaction using a chiral additive
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
US6432994B1 (en) 1997-04-28 2002-08-13 Texas Biotechnology Corporation Sulfonamides for treatment of endothelin-mediated disorders
US6022972A (en) 1997-08-08 2000-02-08 Merck & Co., Inc. Pyridine propanoic acid derivatives
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
US6136971A (en) * 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
US6274585B1 (en) 1998-12-23 2001-08-14 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6680323B2 (en) 1998-12-23 2004-01-20 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
EP1165472A4 (en) 1999-03-19 2002-11-20 Bristol Myers Squibb Co METHOD FOR PRODUCING BIPHENYL ISOXAZOLE
DE19916719A1 (de) * 1999-04-13 2000-10-19 Basf Ag Neue ECE-Inhibitoren, ihre Herstellung und Verwendung
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
HUP0204168A2 (hu) * 1999-12-22 2003-04-28 Actelion Pharmaceuticals Ltd. Butin-diol-származékok, ilyeneket tartalmazó gyógyszerkészítmény és előállítása
US6720322B2 (en) * 1999-12-22 2004-04-13 Actelion Pharamceuticals Ltd. Butyne diol derivatives
EE200200363A (et) 1999-12-31 2003-08-15 Texas Biotechnology Corporation Sulfoonamiidid ja nende derivaadid, mis moduleerivad endoteliini aktiivsust
WO2001055120A1 (en) * 2000-01-25 2001-08-02 F. Hoffmann-La Roche Ag Preparation of sulfonamides
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
US6521632B2 (en) 2000-02-11 2003-02-18 Oy Juvantia Pharma Ltd Method for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor
CZ20022884A3 (cs) * 2000-02-11 2003-02-12 Oy Juvanta Pharma Ltd Sloučeniny užitečné pro léčbu nebo prevenci chorob zprostředkovaných alfa-2B- adrenoceptory
US6720324B2 (en) * 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
MY140724A (en) * 2000-07-21 2010-01-15 Actelion Pharmaceuticals Ltd Novel arylethene-sulfonamides
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
CN100432070C (zh) 2000-12-18 2008-11-12 埃科特莱茵药品有限公司 新颖的磺酰胺类化合物及其作为内皮素受体拮抗剂的应用
PL367040A1 (en) * 2001-07-20 2005-02-21 Oy Juvantia Pharma Ltd Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor
FI116940B (fi) 2001-07-20 2006-04-13 Juvantia Pharma Ltd Oy Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet
FR2831446B1 (fr) * 2001-10-26 2004-03-05 Sanofi Synthelabo Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire
CA2477088A1 (en) 2002-02-22 2003-10-02 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
EP1507756B1 (en) * 2002-05-24 2015-07-22 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
US20040102361A1 (en) * 2002-11-27 2004-05-27 Frederic Bodin Pharmaceutical composition for the treatment of pulmonary arterial hypertension
WO2004050640A1 (en) 2002-12-02 2004-06-17 Actelion Pharmaceuticals Ltd Pyrimidine-sulfamides and their use as endothelian receptor antagonist
US20050101608A1 (en) * 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
NZ549535A (en) 2004-03-17 2010-11-26 Novartis Ag Use of aliskiren for treating renal and other disorders
US20060147520A1 (en) * 2004-07-26 2006-07-06 Curtis Ruegg Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
TW200628467A (en) 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
US7959945B2 (en) * 2005-05-17 2011-06-14 Actelion Pharmaceuticals Ltd. Dispersible bosentan tablet
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
NZ567188A (en) 2005-09-12 2011-04-29 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
EP1951253A2 (en) * 2005-10-26 2008-08-06 Cotherix, Inc. Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
EP2351569B1 (en) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
CA2644784A1 (en) * 2006-03-13 2007-09-20 Jinling Chen Formulations of sitaxsentan sodium
KR20080104149A (ko) * 2006-03-13 2008-12-01 엔싸이시브 파마슈티칼즈 인코퍼레이티드 확장기 심장 부전의 치료를 위한 방법 및 조성물
WO2007119214A2 (en) * 2006-04-13 2007-10-25 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
JP5042311B2 (ja) 2006-07-20 2012-10-03 ノバルティス アーゲー Ｃｅｔｐ阻害剤としてのアミノピペリジン誘導体
AR062501A1 (es) * 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
WO2008088727A2 (en) 2007-01-12 2008-07-24 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8080549B2 (en) * 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
JP2010523584A (ja) * 2007-04-02 2010-07-15 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換ピリミジン
EP2150547A2 (en) * 2007-05-08 2010-02-10 Generics Ýuk¨Limited Polymorphic forms of bosentan
US8664390B2 (en) 2007-06-29 2014-03-04 Generics (Uk) Limited Process for the introduction of hydroxyethoxy side chain in bosentan
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
US20090069351A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched bosentan
WO2009047637A1 (en) * 2007-10-11 2009-04-16 Actavis Group Ptc Ehf Novel polymorphs of bosentan
AU2008315757A1 (en) * 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline forms
JP5555635B2 (ja) 2007-11-05 2014-07-23 ノバルティス アーゲー 高脂血症または動脈硬化症などの疾患の処置に有用なｃｅｔｐ阻害剤としての４−ベンジルアミノ−１−カルボキシアシル−ピペリジン誘導体
ES2425776T3 (es) 2007-12-03 2013-10-17 Novartis Ag Derivados 1,2-disustituidos de 4-bencilamino-pirrolidina como inhibidores CETP útiles para el tratamiento de enfermedades tales como hiperlipidemia o arteriosclerosis
ATE530531T1 (de) * 2007-12-18 2011-11-15 Dipharma Francis Srl Verfahren zur herstellung von bosentan
CA2711043A1 (en) * 2008-01-01 2009-07-09 Cipla Limited Method of synthesis of bosentan, its polymorphic forms and its salts
EP2240470A4 (en) * 2008-01-10 2012-05-23 Msn Lab Ltd IMPROVED AND NEW PROCESS FOR THE PREPARATION OF BOSENTAN
US20110021547A1 (en) * 2008-01-24 2011-01-27 Actavis Group Ptc Ehf Substantially Pure and a Stable Crystalline Form of Bosentan
NZ587793A (en) * 2008-02-08 2012-06-29 Generics Uk Ltd Process for preparing bosentan
CN101279948B (zh) * 2008-03-14 2010-08-11 苏州博鸿化工技术有限公司 4,6-二氯-5-(2-甲氧基苯氧基)-2,2'-二嘧啶的合成方法
WO2009141167A1 (en) * 2008-05-23 2009-11-26 Synthon B.V. Bosentan salts
EP2307019A1 (en) * 2008-06-03 2011-04-13 Fresenius Medical Care Deutschland GmbH Pharmaceutical compositions comprising gamma secretase modulators
WO2010012637A1 (en) * 2008-08-01 2010-02-04 Inke, S.A. Process for the preparation of bosentan
WO2010015623A1 (en) * 2008-08-05 2010-02-11 Farmaprojects, S. A. Process for the preparation of endothelin receptor antagonists
WO2010032261A1 (en) * 2008-08-12 2010-03-25 Cadila Healthcare Limited Process for preparation of bosentan
CN102272108A (zh) * 2008-11-03 2011-12-07 基因里克斯(英国)有限公司 用于分析波生坦及相关物质的hplc方法以及这些物质作为参比标准和标记的用途
IT1393136B1 (it) * 2009-03-11 2012-04-11 Sifa Vitor S R L Procedimento per la preparazione del bosentan
US20100256371A1 (en) * 2009-04-02 2010-10-07 Glenmark Processes for the preparation of bosentan and its intermediates thereof
JP2012523444A (ja) 2009-04-13 2012-10-04 サンド・アクチエンゲゼルシヤフト 内皮受容体アンタゴニスト（ボセンタン）を調製するための方法
ES2430088T3 (es) 2009-05-15 2013-11-18 Novartis Ag Derivados de benzoxazolona como inhibidores de aldosterona sintasa
MY184008A (en) 2009-05-15 2021-03-17 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
ES2602902T3 (es) 2009-05-28 2017-02-22 Novartis Ag Derivados aminopropiónicos sustituidos como inhibidores de neprilisina
CN102448928B (zh) 2009-05-28 2014-10-01 诺华股份有限公司 作为中性溶酶(neprilysin)抑制剂的取代的氨基丁酸衍生物
WO2011024056A2 (en) 2009-08-27 2011-03-03 Aurobindo Pharma Limited An improved process for the preparation of bosentan
AU2010317410B9 (en) 2009-11-12 2014-10-23 Sun Pharmaceutical Industries Limited Crystalline forms of bosentan salts and processes for their preparation
EP2501678B1 (en) 2009-11-17 2015-09-23 Novartis AG Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
EP2507234B1 (en) 2009-11-30 2014-03-12 Novartis AG Imidazole derivatives as aldosterone synthase inhibitors
WO2011070049A1 (en) 2009-12-09 2011-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis
EP2368884A1 (en) 2010-03-25 2011-09-28 Laboratorios Lesvi, S.L. Process for the preparation of bosentan
JP5850576B2 (ja) * 2010-07-06 2016-02-03 富士化学工業株式会社 ボセンタン固体分散体
US9139537B2 (en) 2010-08-11 2015-09-22 Megafine Pharma(P) Ltd. Process for preparation of bosentan
SI2621909T1 (sl) 2010-10-01 2019-04-30 Zach System S.P.A. Postopek za pripravo bosentan monohidrata in njegovih intermediatov
WO2012056468A1 (en) 2010-10-13 2012-05-03 Matrix Laboratories Ltd A process for the preparation of bosentan
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US20130303762A1 (en) 2010-12-03 2013-11-14 Jayaraman Venkat Raman Process for preparing bosentan
ES2386173B1 (es) * 2011-01-13 2013-06-25 Urquima, S.A. Proceso de preparación de un antagonista del receptor de la endotelina
EP2696857A1 (en) 2011-04-11 2014-02-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical composition comprising bosentan
CN102796050B (zh) * 2011-05-23 2014-07-23 昂科生物医学技术(苏州)有限公司 一种Cdc42抑制剂及其应用
WO2013098577A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of bosentan
US20130245259A1 (en) 2012-03-16 2013-09-19 Natco Pharma Limited Process for the preparation of bosentan monohydrate
ITMI20120701A1 (it) 2012-04-27 2013-10-28 Dipharma Francis Srl Procedimento per la purificazione di un composto benzensolfonammidico
CN104487057A (zh) 2012-05-11 2015-04-01 韩诺生物制药株式会社 波生坦控释口服制剂
JP2015521594A (ja) 2012-06-12 2015-07-30 カディラ ファーマシューティカルズ リミテッド ボセンタンの製造方法
US9296705B2 (en) 2012-08-31 2016-03-29 Davuluri Ramamohan Rao 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2(2-pyrimidinyl)-pyrimidine-4-yl)-benzen esulfonamide sodium
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
KR102004422B1 (ko) 2012-12-20 2019-07-26 제일약품주식회사 보센탄 일수화물의 제조방법, 이에 사용되는 신규 중간체 및 이의 제조방법
TR201808541T4 (tr) 2013-02-14 2018-07-23 Novartis Ag Nep (nötr endopeptidaz) inhibitörleri olarak ikame edilmiş bisfenil butanoik fosfonik asit türevleri.
BR112016001376A2 (pt) 2013-07-25 2017-10-24 Novartis Ag bioconjugados de polipeptídeos de apelin sintéticos
BR112016001542A2 (pt) 2013-07-25 2017-08-29 Novartis Ag Polipeptídios cíclicos para o tratamento de insuficiência cardíaca
CN103554037B (zh) * 2013-11-08 2015-03-18 南京靖龙药物研发有限公司 一种波生坦代谢物羟基波生坦的制备方法
PE20171328A1 (es) 2015-01-23 2017-09-12 Novartis Ag Conjugados de acidos grasos y apelina sintetica con mayor vida media
ES2584534B1 (es) 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
PT3468966T (pt) 2016-06-10 2020-11-10 Vitae Pharmaceuticals Llc Inibidores da interação menina-mll
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
TWI833430B (zh) * 2021-11-08 2024-02-21 大陸商正大天晴藥業集團股份有限公司 氮雜聯苯類化合物及其應用
WO2025151724A1 (en) * 2024-01-12 2025-07-17 Rectify Pharmaceuticals, Inc. Pyridinyloxypyridines as modulators of atp -binding cassette transporters and their use in treating medical conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545944A1 (de) * 1964-06-19 1969-12-11 Hoffmann La Roche Verfahren zur Herstellung von neuen Sulfonamiden der Pyrimidinreihe
AU6623690A (en) * 1990-10-29 1992-05-26 Ibrahim Raouf Shimi Novel sulfamide derivatives, a method for obtaining them and their use as a drug

Also Published As

Publication number Publication date
IE921920A1 (en) 1992-12-16
CA2071193C (en) 1998-08-25
US5292740A (en) 1994-03-08
MX9202747A (es) 1994-05-31
LU90976I2 (fr) 2002-12-16
FI112216B (fi) 2003-11-14
CY2004005I2 (el) 2016-08-31
JPH05222003A (ja) 1993-08-31
CY2004005I1 (el) 2009-11-04
CZ281434B6 (cs) 1996-09-11
HU9201930D0 (en) 1992-08-28
IL102138A0 (en) 1993-01-14
EE03028B1 (et) 1997-08-15
NZ243074A (en) 1994-11-25
ES2152222T4 (es) 2011-10-28
LU90975I2 (fr) 2002-12-16
ES2152222T3 (es) 2001-02-01
NO2002012I2 (no) 2005-09-26
BR9202219A (pt) 1993-02-02
KR100235507B1 (ko) 1999-12-15
EP0526708B1 (de) 2000-10-18
HUT63152A (en) 1993-07-28
JPH0730042B2 (ja) 1995-04-05
DK0526708T3 (da) 2001-02-12
DZ1587A1 (fr) 2002-02-17
CY2306B1 (en) 2003-11-14
DE59209872D1 (de) 2000-11-23
DE10299047I2 (de) 2009-11-05
RO111268B (ro) 1996-08-30
DE10299047I1 (de) 2003-03-27
IS3877A (is) 1992-12-14
KR930000489A (ko) 1993-01-15
HU221203B1 (en) 2002-08-28
EP0526708A1 (de) 1993-02-10
FI922746A0 (fi) 1992-06-12
NL300097I1 (nl) 2002-11-01
IL102138A (en) 1996-09-12
AU1812192A (en) 1992-12-17
NO303826B1 (no) 1998-09-07
SG54209A1 (en) 1998-11-16
PT526708E (pt) 2001-04-30
GR3035162T3 (en) 2001-04-30
FI922746L (fi) 1992-12-14
IS2054B (is) 2005-10-14
ZA924126B (en) 1993-02-24
BG60831B2 (bg) 1996-04-30
CA2071193A1 (en) 1992-12-14
AU653604B2 (en) 1994-10-06
RU2086544C1 (ru) 1997-08-10
SK279006B6 (sk) 1998-05-06
NO922323L (no) 1992-12-14
HU211683A9 (en) 1995-12-28
NO922323D0 (no) 1992-06-12
CS180492A3 (en) 1992-12-16
ATE197044T1 (de) 2000-11-15

Similar Documents

Publication Publication Date Title
TW222625B (OSRAM)
TW270116B (OSRAM)
DE3872828D1 (de) Halbleiterkristallplaettchen-stapel.
FI874883L (fi) Genetiskt manipulerade vaextceller och vaexter med resistens foer glutaminsyntesinhibitorer; vid framstaellning av dessa celler och vaexter anvaendbara dna-fragment och -rekombinanter.
DE68920933D1 (de) Produktion von Formiat-Salzen von Stickstoffbasen.
DK336688D0 (da) Nucleosider od fremgangsmaade til fremstilling deraf
BR9916393A (pt) Anel sìncrono produzido sem levantamento de aparas, com áreas estruturadas de fricção
MY108302A (en) Novel sulfonamides
NO864987L (no) Heteroaromatiske acetylener, brukbare som antihypertensive midler.
ES8706653A1 (es) Un procedimiento para la preparacion depropionilamilidas
FI862001A0 (fi) Krok foer fiskande i vatten med undervattensvegetation.
IT207841Z2 (it) Scambio a "t" per impianti a monovia sospesa, per il trasporto di carichi tramite gancio.

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent